Public market insider selling at HLS Therapeutics (HLS)

Public market insider selling at HLS Therapeutics (T:HLS)

Updated Monday Apr 05, 2021 04:44 AM EDT
Gregory David Gubitz, a Director, disposed of 50,000 Common Shares on an indirect ownership basis for registered holder Grosvenor Ventures Inc. at a price of $20.004 on March 30th, 2021. This represents a $1,000,200 divestment of the company's shares and an account share holdings change of -12.5%.

HLS Therapeutics is in the Drug Retailers Sub Industry Group under the Consumer Non-Cyclicals Sector.

HLS Therapeutics Inc is a Canada-based company specialized in the pharmaceutical industry. The Company acquires and distributes commercial stage and branded pharmaceutical drugs for the North American markets. The Company focuses mainly on treatment products for the central nervous system and cardiovascular specialties in Canada. Its product pipeline includes clozaril, for the treatment of schizophrenia disorders; absorica, for treatment of skin disease, such as acne; vascepa, for the treatment of hypertriglyceridemia, and trinomial for cardiovascular risk reduction. Apart from its operation in a number of regions in Canada, such as Toronto, Ontario, and Montreal, the Company also operates in the United States.

Headlines: Apr 05, 2021

HLS Insider Holdings Chart

Issuer details as of Apr 05, 2021 4:44 ET

Latest Price
20.50
1 Day Change
5.13%
52 Week High
21.76
52 Week Low
13.35
QMV ($Mils)
653,224,772


Top